Related Experiment Video
Updated: Feb 20, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma
Venkata Yenugonda1, Natsuko Nomura1, Valentina Kouznetsova2
1John Wayne Cancer Institute and Pacific Neuroscience Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
Background:
The mitochondrial protein p32 is a validated therapeutic target of cancer overexpressed in glioma. Therapeutic targeting of p32 with monoclonal antibody or p32-binding LyP-1 tumor-homing peptide can limit tumor growth. However, these agents do not specifically target mitochondrial-localized p32 and would not readily cross the blood-brain barrier to target p32-overexpressing gliomas. Identifying small molecule inhibitors of p32 overexpressed in cancer is a more rational therapeutic strategy. Thus, in this study we employed a pharmacophore modeling strategy to identify small molecules that could bind and inhibit mitochondrial p32.
Methods:
A pharmacophore model of C1q and LyP-1 peptide association with p32 was used to screen a virtual compound library. A primary screening assay for inhibitors of p32 was developed to identify compounds that could rescue p32-dependent glutamine-addicted glioma cells from glutamine withdrawal. Inhibitors from this screen were analyzed for direct binding to p32 by fluorescence polarization assay and protein thermal shift. Affect of the p32 inhibitor on glioma cell proliferation was assessed by Alamar Blue assay, and affect on metabolism was examined by measuring lactate secretion.
Results:
Identification of a hit compound (M36) validates the pharmacophore model. M36 binds directly to p32 and inhibits LyP-1 tumor homing peptide association with p32 in vitro. M36 effectively inhibits the growth of p32 overexpressing glioma cells, and sensitizes the cells to glucose depletion.
Conclusions:
This study demonstrates a novel screening strategy to identify potential inhibitors of mitochondrial p32 protein overexpressed in glioma. High throughput screening employing this strategy has potential to identify highly selective, potent, brain-penetrant small molecules amenable for further drug development.
Insights
Researchers identified a novel small molecule inhibitor (M36) targeting the mitochondrial protein p32, crucial in glioma. This discovery offers a promising therapeutic strategy for brain tumors by developing brain-penetrant small molecules.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The mitochondrial protein p32 is overexpressed in glioma and represents a validated cancer therapeutic target.
- Current p32-targeting agents like monoclonal antibodies or peptides face limitations in specificity and blood-brain barrier penetration.
- Small molecule inhibitors offer a more rational therapeutic strategy for targeting mitochondrial p32 in gliomas.
Purpose of the Study:
- To employ a pharmacophore modeling strategy to identify small molecules that bind and inhibit mitochondrial p32.
- To develop and validate a screening strategy for identifying potent and selective p32 inhibitors.
Main Methods:
- Utilized a pharmacophore model of p32 association with C1q and LyP-1 peptide to screen a virtual compound library.
- Developed a primary screening assay to identify compounds rescuing p32-dependent glioma cells from glutamine withdrawal.
- Assessed direct p32 binding, inhibition of LyP-1 association, effects on glioma cell proliferation, and metabolism.
Main Results:
- A hit compound, M36, was identified, validating the pharmacophore model.
- M36 demonstrated direct binding to p32 and inhibited LyP-1 peptide association in vitro.
- M36 effectively inhibited p32-overexpressing glioma cell growth and sensitized them to glucose depletion.
Conclusions:
- A novel screening strategy for identifying mitochondrial p32 inhibitors in glioma was successfully demonstrated.
- This approach holds potential for high-throughput screening to discover selective, potent, and brain-penetrant small molecules for glioma drug development.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
